With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues to evolve. To date, the MS market has accommodated a role for many options owing to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. That said, with each new launch—and the recent start of generics competition for Tecfidera—players in this space must assess where their products fit in an increasingly crowded market, especially next-in-class alternatives offering incremental benefits. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain. This national patient-level claims data analysis explores the current DMTs’ positioning, examines line of therapy progression, and assesses persistence and compliance by brand.
Questions Answered
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan, Novartis, Sanofi Genzyme, Teva.
Key drugs covered: Aubagio, Copaxone / glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia.
Key analysis provided:
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution Enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.